Related Experiment Video
Updated: Jun 10, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
Alternative splicing modulates diltiazem sensitivity of cardiac and vascular smooth muscle Ca(v)1.2 calcium channels
Heng Yu Zhang1, Ping Liao, Jue Jin Wang
1Department of Cardiology, West China School of Medicine, Sichuan University, Chengdu, China.
Insights
Diltiazem sensitivity varies between cardiac and smooth muscle Ca(v)1.2 channel variants. Alternative splicing alters channel gating properties, impacting drug response in cardiovascular conditions.
Area of Science:
- Cardiovascular Pharmacology
- Molecular Cardiology
- Ion Channel Physiology
Background:
- Diltiazem, a calcium channel blocker, targets Ca(v)1.2 channels for treating cardiovascular diseases.
- The differential effects of diltiazem on cardiac versus vascular smooth muscle Ca(v)1.2 channel isoforms are not fully understood.
Purpose of the Study:
- To investigate the impact of alternative splicing on diltiazem's effects on Ca(v)1.2 channel variants.
- To compare diltiazem sensitivity and gating properties of cardiac and smooth muscle Ca(v)1.2 splice variants.
Main Methods:
- Expressed cardiac and smooth muscle Ca(v)1.2 channel isoforms in human embryonic kidney cells.
- Utilized whole-cell patch-clamp techniques to characterize electrophysiological properties and diltiazem block.
Main Results:
- Cardiac Ca(v)1.2CM variant showed reduced sensitivity to diltiazem compared to smooth muscle variants (Ca(v)1.2SM, Ca(v)1.2b).
- Ca(v)1.2CM exhibited a more positive half-inactivation potential, with less negative shift by diltiazem and slower current decay.
- Modification of cardiac exons to smooth muscle exons revealed all three loci contribute to differential diltiazem sensitivity.
Conclusions:
- Alternative splicing of Ca(v)1.2 channels significantly modulates diltiazem sensitivity in cardiac and vascular tissues.
- Diltiazem alters gating properties differently across cardiac and smooth muscle Ca(v)1.2 splice variants, influencing therapeutic efficacy.
Background And Purpose:
As a calcium channel blocker, diltiazem acts mainly on the voltage-gated calcium channels, Ca(v)1.2, for its beneficial effects in cardiovascular diseases such as hypertension, angina and/or supraventricular arrhythmias. However, the effects of diltiazem on different isoforms of Ca(v)1.2 channels expressed in heart and vascular smooth muscles remain to be investigated. Here, we characterized the effects of diltiazem on the splice variants of Ca(v)1.2 channels, predominant in cardiac and vascular smooth muscles.
Experimental Approach:
Cardiac and smooth muscle isoforms of Ca(v)1.2 channels were expressed in human embryonic kidney cells and their electrophysiological properties were characterized using whole-cell patch-clamp techniques.
Key Results:
Under closed-channel and use-dependent block (0.03 Hz), cardiac splice variant Ca(v)1.2CM was less sensitive to diltiazem than two major smooth muscle splice variants, Ca(v)1.2SM and Ca(v)1.2b. Ca(v)1.2CM has a more positive half-inactivation potential than the smooth muscle channels, and diltiazem shifted it less to negative potential. Additionally, the current decay was slower in Ca(v)1.2CM channels. When we modified alternatively spliced exons of cardiac Ca(v)1.2CM channels into smooth muscle exons, we found that all three loci contribute to the different diltiazem sensitivity between cardiac and smooth muscle splice isoforms.
Conclusions And Implications:
Alternative splicing of Ca(v)1.2 channels modifies diltiazem sensitivity in the heart and blood vessels. Gating properties altered by diltiazem are different in the three channels.
Related Concept Videos
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...

